公司概覽
業務類別 Biotechnology
業務概覽 Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocytes (TIL) cell therapies for the treatment of patients with solid tumors. The company's proprietary cytoDRiVE platform is versatile and allows it to leverage drug responsive domains to control protein function, with its initial focus on TIL cell therapies developed from this platform (cytoTILs). The company's flagship product candidate, OBX-115, is a novel, genetically engineered, autologous TIL cell therapy currently in a Phase 2 clinical trial for the treatment of melanoma and a Phase 1 clinical trial for the treatment of non-small cell lung cancer.
公司地址 1030 Massachusetts Avenue, Suite 400, Cambridge, MA, USA, 02138
電話號碼 +1 781 806-6245
傳真號碼 --
公司網頁 https://www.obsidiantx.com
員工數量 71
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
沒有相關資料。
 
董事會成員
董事會 職務 更新日期
沒有相關資料。
 
所屬ETF (更新日期: 06/11/2026 03:45)
代號 名稱 佔比% ▼ 持有日期
SCHASchwab US Small-Cap ETF™0.39%31/10/2026
ITOTiShares Core S&P Total US Stock Mkt ETF0.10%30/10/2026
SCHBSchwab US Broad Market ETF™0.05%31/10/2026
ONEQFidelity Nasdaq Composite ETF0.03%30/10/2026
TNXTT. Rowe Price Innovation Leaders ETF0.001%31/10/2026
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.